In response to DNA damaging chemotherapy, targeting MK2 in p53-mutated cells produces a phenotype that is distinct from the p53-deficient phenotype ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2020
• March 2020

There is a strong unmet need to improve systemic therapy in mesothelioma. Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural mesothelioma, and immune checkpoint inhibitors are an emerging treatment in this disease. We aimed to evaluate the activity of durvalumab, an anti-PD-L1 antibody, given during and after first-line chemotherapy with cisplatin and pemetrexed in patients with advanced malignant pleural mesothelioma. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2020
• September 2020

Introduction Grades 2 and 3 gliomas (G2/3 gliomas), when combined, are the second largest group of malignant brain tumours in adults. The outcomes for G2/3 gliomas at progression approach the dismal outcomes for glioblastoma (GBM), yet there is a paucity of trials for Australian patients with relapsed G2/3 gliomas compared with patients with GBM. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• December 2021

These findings implicate the activation of STAT3 as one pathway that may mediate resistance to IGF-II-targeted therapy in HCC ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2018
• August 2018

Research focused on Down syndrome has increased in the last several years to advance understanding of the consequences of trisomy 21 (T21) on molecular and cellular processes and, ultimately, on individuals with Down syndrome. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• July 2021

Acute megakaryoblastic leukemia of Down syndrome (DS-AMKL) is a model of clonal evolution from a preleukemic transient myeloproliferative disorder requiring both a trisomy 21 (T21) and a GATA1s mutation to a leukemia driven by additional driver mutations. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2022
• July 2022

Haematological malignancies, although a broad range of specific disease types, continue to show considerable overlap in classification, and patients are... ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2015
• May 2015

Epigenetically regulated genes have a great theranostic potential, especially in tumors with no apparent driver mutations. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2017
• October 2017

We found no evidence of positive associations between risk of childhood brain tumours overall and childhood or parental pre-pregnancy radiological procedures. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2014
• January 2014

Anti-cancer chemotherapy can be simultaneously lymphodepleting and immunostimulatory. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2009
• September 2009

Rare childhood cancers have not benefited to the same extent from the gains that have been made for their frequently occurring counterparts. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2015
• February 2015

Laurence Rishi Sury Sébastien Cheung Kotecha Malinge LC RS SM BPharm (Hons) MBA PhD MB ChB (Hons) MRCPCH FRACP PhD PhD Co-Head, Leukaemia Translational Research Co-Head, Leukaemia Translational Research Laboratory Head, Translational Genomics in ...

• 1. Telethon Kids Institute
• Projects